Loading
The worldwide register of people who kept their rectum after treatment. A quarter of the cancers regrow, almost all within two years and almost all in the bowel wall where they can be found and removed.
The International Watch & Wait Database pooled individual patient data from 47 institutes in 15 countries for people whose rectal cancer was managed without surgery after a clinical complete response to neoadjuvant treatment. Of 1,009 patients identified, 880 had a clinical complete response. The two-year cumulative incidence of local regrowth was 25.2 percent (95% CI 22.2 to 28.5); 88 percent of regrowth appeared in the first two years and 97 percent was in the bowel wall, where endoscopic surveillance finds it and salvage surgery is possible. Distant metastases occurred in 8 percent. Five-year overall survival was 85 percent and disease-specific survival 94 percent. The registry is the evidence base for offering watch and wait outside a trial and sets the surveillance schedule: endoscopy and MRI every three to four months for two years.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,009 registered.
Shares PROSPECT (Alliance N1048), PRODIGE 23, OPRA, Clinical complete response (cCR).
Shares RAPIDO, PRODIGE 23, OPRA, Chemoradiation (chemoradiotherapy, CRT).
Shares RAPIDO, PRODIGE 23, Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam).
Shares PROSPECT (Alliance N1048), RAPIDO, IMRT / IGRT (modern external beam), Rectal cancer.
Shares RAPIDO, AZUR-1, PRODIGE 23, OPRA.
Shares PROSPECT (Alliance N1048), Rectal cancer.
Shares PRODIGE 23, Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam), Rectal cancer.
Shares RAPIDO, IMRT / IGRT (modern external beam), Rectal cancer, Colorectal cancer.